A global research program does not make every regional population interchangeable. REDEFINE 5 studied CagriSema against semaglutide in Japan and Taiwan, providing evidence from a defined regional setting. Its contribution is most useful when its eligibility rules and active comparator remain visible.
Who participated?
The double-blind phase 3a trial randomized 331 adults at sites in Japan and Taiwan; 24% had type 2 diabetes. Eligibility combined BMI thresholds with specified numbers of obesity-related complications. At 68 weeks, estimated mean weight change under the primary trial-product estimand was −18.4% with the combination and −11.9% with semaglutide. See the primary REDEFINE 5 publication.
Those criteria matter. A reader should not assume the result describes every person of East Asian ancestry or every adult living in the participating countries. A regional study remains a selected study population, with its own clinical entry requirements.
The comparator was an active medicine
This trial compared the combination directly with semaglutide, alongside lifestyle intervention. That makes its central comparison different from a placebo-controlled result. The reported estimated difference was −6.5 percentage points under the primary analysis.
Do not substitute a placebo figure from another trial to create a more dramatic contrast. Keeping the randomized comparison intact provides a more honest account of what the experiment established.
Do not use separate trials to diagnose an ethnic effect
If another CagriSema study reports a different average, that difference does not prove that ethnicity caused a different response. Trials can differ in eligibility, baseline health, diabetes prevalence, duration and analysis. Participants were not randomized between regional identities.
The useful question is whether the regional study reduces a particular uncertainty about relevance to a patient’s circumstances. It should not become a deterministic prediction based on ancestry.
Read tolerability alongside efficacy
Gastrointestinal disorders were the most common adverse events in both active groups. The publication also reports treatment discontinuations, reminding readers that an efficacy estimate and the practical experience of treatment are distinct parts of the evidence.
For a consultation, ask how closely the study’s clinical eligibility matches your situation, which endpoint matters to you, and what the active-comparator result adds to the discussion. Regional relevance can improve an evidence assessment without creating an individualized forecast.
Finally, study location does not establish present local approval or supply. Any proposed medicine needs a separate, current status check in the country where care is delivered. This research summary does not establish a treatment offer or authorize changing an existing prescription.
Sources and reading scope
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.